Innoviva, Inc. (NASDAQ:INVA)‘s stock had its “neutral” rating reissued by investment analysts at Stifel Nicolaus in a research note issued to investors on Friday.

INVA has been the subject of a number of other reports. ValuEngine lowered shares of Innoviva from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research lowered shares of Innoviva from a “hold” rating to a “sell” rating in a report on Monday, July 3rd. Cowen and Company set a $16.00 target price on shares of Innoviva and gave the company a “buy” rating in a report on Friday, July 28th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $13.00 target price (up from $11.00) on shares of Innoviva in a report on Thursday, July 27th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Innoviva currently has a consensus rating of “Hold” and an average target price of $15.00.

Shares of Innoviva (INVA) opened at 13.87 on Friday. Innoviva has a one year low of $8.67 and a one year high of $14.55. The stock has a 50 day moving average of $13.18 and a 200-day moving average of $12.78. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of 17.45 and a beta of 2.58.

Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, July 26th. The biotechnology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.02. Innoviva had a net margin of 52.56% and a negative return on equity of 27.37%. The firm had revenue of $58.60 million during the quarter, compared to analyst estimates of $50.53 million. During the same period last year, the firm posted $0.13 earnings per share. Innoviva’s revenue for the quarter was up 80.3% compared to the same quarter last year. On average, equities analysts expect that Innoviva will post $1.16 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/17/innoviva-inc-inva-rating-reiterated-by-stifel-nicolaus.html.

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in Innoviva by 68,215.3% during the first quarter. BlackRock Inc. now owns 12,000,259 shares of the biotechnology company’s stock worth $165,964,000 after buying an additional 11,982,693 shares during the period. Comerica Bank boosted its stake in Innoviva by 4.5% during the first quarter. Comerica Bank now owns 85,950 shares of the biotechnology company’s stock worth $1,082,000 after buying an additional 3,673 shares during the period. Trexquant Investment LP purchased a new position in Innoviva during the first quarter worth $818,000. Morgan Stanley boosted its stake in Innoviva by 92.2% during the first quarter. Morgan Stanley now owns 564,427 shares of the biotechnology company’s stock worth $7,807,000 after buying an additional 270,824 shares during the period. Finally, KCG Holdings Inc. boosted its stake in Innoviva by 63.9% during the first quarter. KCG Holdings Inc. now owns 30,265 shares of the biotechnology company’s stock worth $419,000 after buying an additional 11,802 shares during the period. 69.07% of the stock is owned by institutional investors.

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Stock Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related stocks with our FREE daily email newsletter.